This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garau, M.
Right arrow Articles by del Palacio, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garau, M.
Right arrow Articles by del Palacio, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2003, p. 2342-2344, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2342-2344.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Susceptibilities of Malassezia Species to a New Triazole, Albaconazole (UR-9825), and Other Antifungal Compounds

Margarita Garau,1 Manolo Pereiro Jr.,2 and Amalia del Palacio1*

Department of Microbiology, Hospital Universitario 12 de Octubre, Madrid,1 Department of Dermatology, Complejo Hospitalario Universitario, Faculty of Medicine, Santiago de Compostela, Spain2

Received 26 December 2002/ Returned for modification 12 March 2003/ Accepted 17 April 2003


arrow
ABSTRACT
 
The in vitro activity of the new triazole albaconazole (UR-9825) in comparison with those of flucytosine, fluconazole, ketoconazole, itraconazole, and voriconazole against 70 strains of Malassezia spp. was determined by a microdilution method using a colorimetric indicator for metabolic activity. Albaconazole showed an in vitro profile similar to those of the different antifungals tested (MIC <= 0.06 µg/ml for all the strains).


arrow
TEXT
 
Yeasts of the genus Malassezia are part of the normal mycota of the skin of humans and other warm-blooded animals, particularly in areas rich in sebaceous glands (19). Malassezia species may also be etiological agents of skin disorders and, uncommonly, systemic infections (3, 6, 16, 24, 30).

In 1997, the National Committee for Clinical Laboratory Standards approved a broth micro- and macrodilution method for susceptibility testing of yeasts with RPMI 1640 medium (NCCLS-M27A) (21). However, this document is not applicable to Malassezia species other than Malassezia pachydermatis, because these organisms do not grow without lipidic substances in the medium. Only a few systems for in vitro susceptibility testing of Malassezia species have been described. In addition to present measurements in solid media, several microdilution methods have been used, but the different liquid media used, such as modified Dixon (19, 27) and Leeming-Notman (15), are turbid; consequently, the visual and turbidimetric results are difficult to interpret. A liquid medium method has been observed to overcome the difficulties in growth reading if one uses a colorimetric indicator for metabolic activity (Alamar blue) (25). Recently, Nakamura et al. (20) described a new microdilution method based on the urease activity of Malassezia spp.

Albaconazole (ABC) is a new systemic triazole under development by J. Uriach & Cia S.A. (Barcelona, Spain) with both potent and broad-spectrum antifungal activity, good pharmacokinetics, and excellent bioavailability. It has demonstrated good in vitro activities against pathogenic yeasts (23), dermatophytes (10), and some filamentous fungi (4), including Scedosporium prolificans (5). It has also been shown to be active in the treatment of systemic aspergillosis and candidiasis in experimental animal models (2).

The aim of this study was to compare the in vitro activity of ABC with those of five antifungal drugs, namely, flucytosine (5FC), fluconazole (FLC), ketoconazole (KTC), itraconazole (ITC), and voriconazole (VRC), against 70 isolates of Malassezia, namely, M. furfur (n = 24), M. pachydermatis (n = 10), M. sympodialis (n = 21), and M. slooffiae (n = 15). M. furfur was obtained from human skin, that of neonates with long stays in intensive care units. M. pachydermatis and M. slooffiae were obtained from healthy and diseased ears of dogs and pigs, respectively. M. sympodialis was isolated from normal human skin. Susceptibility testing of the drugs was initially performed with M. restricta (n = 1), M. obtusa (n = 1), and M. globosa (n = 24). However, we were unable to obtain MICs due to the slow growth of these species. Identification of the different Malassezia strains to the species level was done following the guidelines of Guillot et al. (11) and Mayser et al. (18). In some cases and because of ambiguity of the mentioned tests, we also identified the strains by molecular analysis as described by Gupta et al. (12). The isolates were maintained by culturing on modified Dixon agar at 32°C and were subcultured weekly more than three times before use.

All drugs were obtained as powders from single batches and were stored desiccated in the dark at 4°C and were provided by their respective manufacturers: 5FC (ICN Iberica, Barcelona, Spain), FLC and VRC (Pfizer, Madrid, Spain), KTC and ITC (Janssen Research Foundation, Beerse, Belgium), and ABC (J. Uriach & Cia S.A.). Stock solutions of KTC, ITC, VRC and ABC were prepared in dimethyl sulfoxide (Sigma, St. Louis, Mo.) at concentrations of 1,600 µg/ml for KTC, ITC, and VRC and 3,200 µg/ml for UR-9825. Solutions of 5FC and FLC were prepared in distilled water at concentrations of 1,280 µg/ml. All the solutions were stored in the dark at -70°C and were used within 3 months. KTC, ITC, and VRC were tested in a concentration range between 0.03 and 16 µg/ml. The range of ABC was 0.06 to 32 µg/ml. FLC and 5FC were tested in a concentration range between 0.125 and 64 µg/ml.

The method described by Schmidt and Rühl-Hörster (25) for M. furfur and by Palacin et al. (22) for M. furfur and M. pachydermatis was used. Inocula were prepared by growing organisms on modified Dixon's agar at 32°C for 5 days. Colonies were suspended in Leeming-Notman medium, and suspensions were adjusted to 1 x 104 to 5 x 104 CFU/ml as determined by viable counts. Fifty microliters of each working solution was pipetted into each well of a 96-well microtiter plate in U form containing 50 µl of each prepared inoculum suspension. Growth and sterility control wells were also included. The plates were protected from evaporation by placing them in a humid chamber, and their contents were subsequently incubated at 32°C for 3 days. Because of the medium turbidity, the inhibition of growth or lack of growth of organisms was determined by a nonturbidimetric method. Alamar blue (AccuMed) is a colorimetric indicator of growth based on the detection of metabolic activity. It was diluted (1:4) in phosphate-buffered saline (Sigma), and 50 µl of this solution was added to each well after the last period of incubation. After another 24 h of incubation, visual reading of plates was performed. In the case of metabolic activity of the organisms, a change from blue to pink occurred. The lowest drug concentration preventing the color turning from blue to pink was defined as the MIC.

The in vitro results are shown in Table 1. All the strains were in vitro resistant to 5FC (MIC > 64 µg/ml). These results are in agreement with those obtained by Marcon et al. (17), who tested amphotericin B, 5FC, KTC, and miconazole against 15 systemic and 10 superficial M. furfur isolates and observed that 5FC was the least active drug in vitro (MIC > 100 µg/ml). Danker and Spector (7) reported a single M. furfur catheter blood culture isolate for which the MIC was > 100 µg of 5FC/ml.


View this table:
[in this window]
[in a new window]
  		TABLE 1. MIC (µg/ml) of 5FC, FLC, KTC, ITC, VRC, and ABC against 70 Malassezia isolates

KTC had MICs of <=0.03 µg/ml. These data are consistent with those documented in the literature: Schmidt and Rühl-Hörster (25) measured KTC MICs for 30 strains of M. furfur and observed that for 29 of 30 strains the MIC was <= 0.06 µg/ml. Gupta et al. (13) reported that, for 95% (52 of 55) of strains tested for susceptibility to KTC, the MIC was <= 0.03 µg/ml (for only three strains the MIC was 0.125 µg/ml). Hammer et al. (14) studied the in vitro activity of KTC, econazole, and miconazole against 54 Malassezia isolates and observed that the most potent inhibitor in vitro was KTC (0.03 to 0.25 µg/ml). These findings are similar to those of previous reports (9, 16, 28, 29).

MICs of FLC for Malassezia species ranged from 0.25 to 4 µg/ml, these values being similar to or lower than those reported by Strippoli et al. (MIC, 4.1 µg/ml) (26).

The MIC data for ITC are comparable with those reported in previous studies. MICs of ITC for Malassezia species ranged from <=0.03 to 0.06 µg/ml. Ahn et al. (1) obtained MICs of ITC for M. furfur strains between 0.015 and 0.06 µg/ml; these values were lower than those reported by Faergemann (MICs, 0.1 to 0.2 µg/ml) (8). Strippoli et al. (26) studied the in vitro activity of several antifungal agents (KTC, miconazole, econazole, fenticonazole, ITC, and FLC) against M. furfur isolates from pityriasis versicolor lesions and observed that ITC and KTC were the most active drugs, with a MIC of 0.8 µg/ml for both.

Our MICs of VRC for Malassezia species ranged from <=0.03 to 0.12 µg/ml. These results are in agreement with those obtained by Gupta et al. (13), who tested 55 strains of Malassezia species with VRC and obtained MICs ranging from <=0.03 to 0.25 µg/ml.

To our knowledge, the present study is the first to investigate the in vitro activity of ABC against lipophilic yeasts. From our data, ABC seems to be in vitro active against Malassezia spp. and the clinical activity of this compound should be explored and compared in the future with those of other available drugs for the management of clinical conditions associated with lipophilic yeasts.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Microbiology, Hospital Universitario 12 de Octubre, Carretera de Andalucía, km 5.4, 28041, Madrid, Spain. Phone: 91 390 82 39. Fax: 91 390 83 58. E-mail: m.amengual{at}palmapan.es. Back


arrow
REFERENCES
 
    1
  1. Ahn, K. J., and H. R. Ashbee. 1996. Determination of minimum inhibitory concentrations of several azole antifungals for Malassezia furfur. Ann. Dermatol. 8:187-194.
    2. 2
  2. Bartrolí, J., E. Turmo, M. Algueró, E. Boncompte, M. L. Vericat, L. Conte, J. Ramis, M. Merlos, J. García-Rafanell, and J. Forn. 1998. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted 4 (3H)-quinazolinones. J. Med. Chem. 41:1869-1882.[CrossRef][Medline]
    3. 3
  3. Belkum, A., T. Boekhout, and R. Bosboom. 1994. Monitoring spread of Malassezia infections in a neonatal intensive care unit by PCR-mediated genetic typing. J. Clin. Microbiol. 32:2528-2532.[Abstract/Free Full Text]
    4. 4
  4. Capilla, J., M. Ortoneda, F. J. Pastor, and J. Guarro. 2001. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob. Agents Chemother. 45:2635-2637.[Abstract/Free Full Text]
    5. 5
  5. Carrillo, A. J., and J. Guarro. 2001. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45:2151-2153.[Abstract/Free Full Text]
    6. 6
  6. Crespo Erchiga, V., A. Ojeda Martos, A. Vera Casano, A. Crespo Erchiga, and F. Sanchez Fajardo. 1999. Aislamiento e identificación de Malassezia spp. en pitiriasis versicolor, dermatitis seborreica y piel sana. Rev. Iberoam. Micol. 16:S16-S21.[Medline]
    7. 7
  7. Danker, W. M., and S. A. Spector. 1985. Malassezia furfur sepsis in neonates. J. Pediatr. 197:643-644.
    8. 8
  8. Faergemann, J. 1984. In vitro and in vivo activities of ketoconazole and itraconazole against Pityrosporum orbiculare. Antimicrob. Agents Chemother. 26:773-774.[Abstract/Free Full Text]
    9. 9
  9. Faergemann, J., and M. Borgers. 1990. The effect of ketoconazole and itraconazole on the filamentous form of Pityrosporum ovale. Acta Dermat.-Venereol. 70:172-176.
    10. 10
  10. Fernandez-Torres, B., A. J. Carrillo, E. Martín, A. del Palacio, M. K. Moore, A. Valverde, M. Serrano, and J. Guarro. 2001. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob. Agents Chemother. 45:2524-2528.[Abstract/Free Full Text]
    11. 11
  11. Guillot, J., E. Guého, M. Lesourd, G. Midgley, G. Chevrier, and B. Dupont. 1996. Identification of Malassezia species: a practical approach. J. Med. Mycol. 6:103-110.
    12. 12
  12. Gupta, A. K., Y. Kohli, and R. C. Summerbell. 2000. Molecular differentiation of seven Malassezia species. J. Clin. Microbiol. 38:1869-1875.[Abstract/Free Full Text]
    13. 13
  13. Gupta, A. K., Y. Kholi, A. Li., J. Faergemann, and R. C. Summerbell. 2000. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. J. Clin. Microbiol. 142:758-765.
    14. 14
  14. Hammer, K. A., C. F. Carson, and T. V. Riley. 2000. In vitro activities of ketoconazole, econazole, miconazole, and Melaleuca alternifolia (tea tree) oil against Malassezia species. Antimicrob. Agents Chemother. 44:467-469.[Abstract/Free Full Text]
    15. 15
  15. Leeming, J. P., and F. H. Notman. 1987. Improved methods for isolation and enumeration of Malassezia furfur from human skin. J. Clin. Microbiol. 25:2017-2019.[Abstract/Free Full Text]
    16. 16
  16. Marcon, M. J., and D. A. Powell. 1992. Human infections due to Malassezia species. Clin. Microbiol. Rev. 5:101-119.[Abstract/Free Full Text]
    17. 17
  17. Marcon, M. J., D. E. Durrell, D. A. Powell, and W. J. Buesching. 1987. In vitro activity of systemic antifungal agents against Malassezia furfur. Antimicrob. Agents Chemother. 31:951-953.[Abstract/Free Full Text]
    18. 18
  18. Mayser, P., P. Haze, C. Papavassilis, M. Pickel, K. Gruender, and E. Guého. 1997. Differentiation of Malassezia species: selectivity of Cremophor EL, castor oil and ricinoleic acid for M. furfur. Br. J. Dermatol. 137:209-213.
    19. 19
  19. Midgley, G. 1989. The diversity of Pityrosporum (Malassezia) yeasts in vivo and in vitro. Mycopathologia 106:143-153.[CrossRef][Medline]
    20. 20
  20. Nakamura, Y., R. Kano, T. Murai, S. Watanabe, and A. Hasegawa. 2000. Susceptibility testing of Malassezia species using the urea broth microdilution method. Antimicrob. Agents Chemother. 44:2185-2186.[Abstract/Free Full Text]
    21. 21
  21. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    22. 22
  22. Palacin, C., C. Tarragó, and J. A. Ortiz. 1998. In vitro activity of sertaconazole against Malassezia furfur and pachydermatis in different culture media. Methods Find. Exp. Clin. Pharmacol. 20:451-455.[CrossRef][Medline]
    23. 23
  23. Ramos, G., M. Cuenca-Estrella, A. Monzon, and J. L. Rodríguez-Tudela. 1999. In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J. Antimicrob. Chemother. 44:283-286.[Abstract/Free Full Text]
    24. 24
  24. Richet, H. M., M. M. McNeil, M. C. Edwards, and W. R. Jarvis. 1989. Cluster of Malassezia furfur pulmonary infections in a neonatal intensive care unit. J. Clin. Microbiol. 27:1197-1200.[Abstract/Free Full Text]
    25. 25
  25. Schmidt, A., and B. Rühl-Hörster. 1996. In vitro susceptibility of Malassezia furfur against azole compounds. Mycoses 39:309-312.[Medline]
    26. 26
  26. Strippoli, V., A. Piacentini, F. D. D'Auria, and N. Simonetti. 1997. Antifungal activity of ketoconazole and other azoles against Malassezia furfur in vitro and in vivo. Infection 25:303-306.[CrossRef][Medline]
    27. 27
  27. Van Abbe, N. J. 1964. The investigation of dandruff. J. Soc. Cosmet. Chem. 15:609-630.
    28. 28
  28. Van Cutsem, J., F. Van Gerven, J. Fransen, P. Schrooten, and P. A. J. Janssen. 1989. The in vitro antifungal activity of ketoconazole, zinc pyrithione, and selenium sulfide against Pityrosporum and their efficacy as a shampoo in the treatment of experimental pityrosporosis in guinea pigs. J. Am. Acad. Dermatol. 22:993-998.
    29. 29
  29. Van Gerven, F., and F. C. Odds. 1995. The anti-Malassezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents: bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole, and sertaconazole. Mycoses 38:389-393.[Medline]
    30. 30
  30. Welbel, S. F., M. M. McNeil, A. Pramanik, R. Silberman, A. D. Orbele, G. Midgley, S. Crow, and W. R. Jarvis. 1994. Nosocomial Malassezia pachydermatis bloodstream infections in a neonatal intensive care unit. Pediatr. Infect. Dis. J. 13:104-108.[Medline]

Antimicrobial Agents and Chemotherapy, July 2003, p. 2342-2344, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2342-2344.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pasqualotto, A. C., Denning, D. W. (2008). New and emerging treatments for fungal infections. J Antimicrob Chemother 61: i19-i30 [Abstract] [Full Text]  
  • Rincon, S., Cepero de Garcia, M. C., Espinel-Ingroff, A. (2006). A Modified Christensen's Urea and CLSI Broth Microdilution Method for Testing Susceptibilities of Six Malassezia Species to Voriconazole, Itraconazole, and Ketoconazole.. J. Clin. Microbiol. 44: 3429-3431 [Abstract] [Full Text]  
  • Sugita, T., Tajima, M., Ito, T., Saito, M., Tsuboi, R., Nishikawa, A. (2005). Antifungal Activities of Tacrolimus and Azole Agents against the Eleven Currently Accepted Malassezia Species. J. Clin. Microbiol. 43: 2824-2829 [Abstract] [Full Text]  
  • Velegraki, A., Alexopoulos, E. C., Kritikou, S., Gaitanis, G. (2004). Use of Fatty Acid RPMI 1640 Media for Testing Susceptibilities of Eight Malassezia Species to the New Triazole Posaconazole and to Six Established Antifungal Agents by a Modified NCCLS M27-A2 Microdilution Method and Etest. J. Clin. Microbiol. 42: 3589-3593 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garau, M.
Right arrow Articles by del Palacio, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garau, M.
Right arrow Articles by del Palacio, A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»